Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - olanzapine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; hyprolose; microcrystalline cellulose; lactose monohydrate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; methylcellulose; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; macrogol 600; basic butylated methacrylate copolymer - treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 7.5 mg - tablet, uncoated - excipient ingredients: hyprolose; lactose; microcrystalline cellulose; magnesium stearate - apo-olanzapine tablets are indicated for ? treatment of schizophrenia and related psychoses. ? short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. ? preventing recurrence of manic, mixed or depressive episodes in bipolar 1 disorder.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose; hyprolose - apo-olanzapine tablets are indicated for ? treatment of schizophrenia and related psychoses. ? short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. ? preventing recurrence of manic, mixed or depressive episodes in bipolar 1 disorder.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; magnesium stearate - apo-olanzapine tablets are indicated for ? treatment of schizophrenia and related psychoses. ? short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. ? preventing recurrence of manic, mixed or depressive episodes in bipolar 1 disorder.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

johnson & johnson pacific pty ltd - domperidone, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; pregelatinised potato starch; povidone; sodium lauryl sulfate; maize starch; hypromellose; lactose monohydrate; hydrogenated cottonseed oil; microcrystalline cellulose - for the short term treatment in adults of: 1. symptoms associated with idiopathic or diabetic gastroparesis(once control of diabetes has been established by diet and/or insulin, attempt should be made to discontinue motilium) 2. intractable nausea and vomiting from any cause.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - domperidone maleate, quantity: 12.72 mg (equivalent: domperidone, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; povidone; sodium lauryl sulfate; lactose monohydrate; maize starch - apo-domperidone is indicated for the short-term treatment in adults of:,? symptoms associated with idiopathic or diabetic gastroparesis (once control of diabetes has been established by diet and/or insulin, an attempt should be made to discontinue apo-domperidone).,? intractable nausea and vomiting from any cause.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - quetiapine fumarate, quantity: 230.284 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; sodium starch glycollate type a; magnesium stearate; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 400 - quetiapine rbx tablets are indicated for: bipolar disorder = maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes = treatment of depressive episodes associated with bipolar disorder (see dosage and administration) = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate schizophrenia = treatment of schizophrenia

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - quetiapine fumarate, quantity: 28.785 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; calcium hydrogen phosphate dihydrate; povidone; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - quetiapine rbx tablets are indicated for: bipolar disorder = maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes = treatment of depressive episodes associated with bipolar disorder (see dosage and administration) = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate schizophrenia = treatment of schizophrenia

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - quetiapine fumarate, quantity: 115.142 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a; lactose monohydrate; calcium hydrogen phosphate dihydrate; povidone; titanium dioxide; hypromellose; purified talc; macrogol 400 - quetiapine rbx tablets are indicated for: bipolar disorder = maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes = treatment of depressive episodes associated with bipolar disorder (see dosage and administration) = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate schizophrenia = treatment of schizophrenia